Pharmaceutical

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

TCR therapies are minimally engineered and can target both cell surface antigens and intracellular antigens.

Aug 11, 2024 - 04:00
Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval
TCR therapies are minimally engineered and can target both cell surface antigens and intracellular antigens.
Read the original article

Tags:

Previous Article

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

Next Article

Gilead Sciences reports net income rise in Q2 2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Zai Lab and argenx announce NMPA approval for sBLA for VYVGART Hytrulo

Zai Lab and argenx announce NMPA approval for sBLA for ...

Nov 13, 2024

GSK’s Omjjara gains approval in Japan for myelofibrosis treatment

GSK’s Omjjara gains approval in Japan for myelofibrosis...

Jun 26, 2024

Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review

Regeneron’s bispecific lymphoma antibody odronextamab w...

Sep 29, 2023